Eterna Therapeutics Inc (ERNA) Stock Price, Quote & News

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The compa...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 582 1199

Website: www.ernexatx.com

Address:

1035 Cambridge Street, Suite 18A, Cambridge, United States

MrGekko2u Mar. 20 at 11:19 PM

$ERNA shake shake shake

1 · Reply

breakeven2 Mar. 20 at 11:02 PM

$ERNA what the F is this now (( https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/form8-k.htm )) Ernexa Therapeutics faces Nasdaq delisting notice after bid price falls below $1 for 30 days

0 · Reply

M1Tanker Mar. 20 at 10:04 PM

$ERNA out for now.

0 · Reply

M1Tanker Mar. 20 at 7:47 PM

$ERNA ✅️

0 · Reply

M1Tanker Mar. 20 at 6:55 PM

$ERNA 🤔

0 · Reply

M1Tanker Mar. 20 at 3:41 PM

$ERNA

0 · Reply

M1Tanker Mar. 20 at 2:51 PM

$ERNA warrants at .68

0 · Reply

M1Tanker Mar. 20 at 12:06 PM

$ERNA 🛫🛫🛫

0 · Reply

M1Tanker Mar. 20 at 11:15 AM

$ERNA 🙌👇

0 · Reply

24DV4NC3D Mar. 18 at 8:06 PM

$ERNA ⚡️WHAT DID I SAY?!⚡️ STOCK OF THE DAY - WILDCARD #1 >>>>> #LISTEN! <<<<< >>>>>>> OVERSOLD! <<<<<<< PIVOT … .61 🎯R1 … .96 🎯R2 (! …1.63 (!) >>>>>>> LISTEN <<<<<<<

0 · Reply

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Feb 6, 2026, 9:25 AM EST - 6 weeks ago

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Feb 3, 2026, 8:45 AM EST - 6 weeks ago

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Jan 27, 2026, 8:45 AM EST - 7 weeks ago

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Jan 6, 2026, 8:15 AM EST - 2 months ago

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Dec 8, 2025, 8:30 AM EST - 3 months ago

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Dec 3, 2025, 8:30 AM EST - 3 months ago

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Dec 2, 2025, 8:50 AM EST - 3 months ago

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Nov 11, 2025, 7:00 AM EST - 4 months ago

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Nov 10, 2025, 8:35 AM EST - 4 months ago

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Nov 6, 2025, 9:15 AM EST - 4 months ago

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Oct 29, 2025, 8:33 AM EDT - 5 months ago

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Oct 1, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Sep 29, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Sep 17, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Sep 10, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Sep 3, 2025, 9:30 AM EDT - 7 months ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Jul 9, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jun 25, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Jun 24, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Jun 10, 2025, 9:30 AM EDT - 10 months ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

May 28, 2025, 8:30 AM EDT - 10 months ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 14, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 8, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 29, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 3, 2025, 8:55 AM EDT - 1 year ago

Ernexa Therapeutics Closes New Funding Round

Feb 26, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Jan 14, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 9, 2025, 7:30 AM EST - 1 year ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Nov 14, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

May 10, 2024, 8:00 AM EDT - 2 years ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 8, 2024, 9:31 AM EDT - 2 years ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Feb 20, 2024, 8:30 AM EST - 2 years ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Jan 3, 2024, 4:15 PM EST - 2 years ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Dec 20, 2023, 4:15 PM EST - 2 years ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Dec 14, 2023, 6:56 PM EST - 2 years ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Nov 1, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

May 24, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

May 17, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 4, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 2, 2023, 7:30 AM EDT - 3 years ago

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Apr 11, 2023, 8:00 AM EDT - 3 years ago

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

Mar 28, 2023, 8:30 AM EDT - 3 years ago

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

Mar 20, 2023, 4:10 PM EDT - 3 years ago

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

MrGekko2u Mar. 20 at 11:19 PM

$ERNA shake shake shake

1 · Reply

breakeven2 Mar. 20 at 11:02 PM

0 · Reply

M1Tanker Mar. 20 at 10:04 PM

$ERNA out for now.

0 · Reply

M1Tanker Mar. 20 at 7:47 PM

$ERNA ✅️

0 · Reply

M1Tanker Mar. 20 at 6:55 PM

$ERNA 🤔

0 · Reply

M1Tanker Mar. 20 at 3:41 PM

$ERNA

0 · Reply

M1Tanker Mar. 20 at 2:51 PM

$ERNA warrants at .68

0 · Reply

M1Tanker Mar. 20 at 12:06 PM

$ERNA 🛫🛫🛫

0 · Reply

M1Tanker Mar. 20 at 11:15 AM

$ERNA 🙌👇

0 · Reply

24DV4NC3D Mar. 18 at 8:06 PM

$ERNA ⚡️WHAT DID I SAY?!⚡️ STOCK OF THE DAY - WILDCARD #1 >>>>> #LISTEN! <<<<< >>>>>>> OVERSOLD! <<<<<<< PIVOT … .61 🎯R1 … .96 🎯R2 (! …1.63 (!) >>>>>>> LISTEN <<<<<<<

0 · Reply

Tusto Mar. 16 at 8:28 PM

$ERNA = scam

1 · Reply

ChartChartist Mar. 16 at 2:22 AM

$AEHL Squeeze knows. Be sure to follow him $FIG play in the fire $ERNA my love $GNS the big boy Aehl top play monday tuesday

0 · Reply

Freak_Trades Mar. 15 at 3:51 PM

$AEHL Let's see if they let this go. Room IMO $CLIK This looks good! $CJMB I like it! $ERNA Swinging.

0 · Reply

Mike_Rotsch Mar. 13 at 3:45 PM

$ERNA I'm not selling, lol. This is getting ready to pop hard. And just before every pop, you can expect a little dance to grab our shares from us first.

0 · Reply